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ABSTRACT We identiﬁed a strain of Actinomyces ruminicola which produces a po-
tent bacteriocin with activity against a broad range of Gram-positive bacteria, many
of which are pathogenic to animals and humans. The bacteriocin was puriﬁed and
found to have a mass of 4,091  1 Da with a sequence of GFGCNLITSNPYQCSNHCKS
VGYRGGYCKLRTVCTCY containing three disulﬁde bridges. Surprisingly, near relatives
of actifensin were found to be a series of related eukaryotic defensins displaying
greater than 50% identity to the bacteriocin. A pangenomic screen further revealed
that production of actifensin-related bacteriocins is a common trait within the ge-
nus, with 47 being encoded in 161 genomes. Furthermore, these bacteriocins dis-
played a remarkable level of diversity with a mean amino acid identity of only 52%
between strains/species. This level of redundancy suggests that this new class of
bacteriocins may provide a very broad structural basis on which to deliver and de-
sign new broad-spectrum antimicrobials for treatment of animal and human infec-
tions.
IMPORTANCE Bacteriocins (ribosomally produced antimicrobial peptides) are poten-
tial alternatives to current antimicrobials given the global challenge of antimicrobial
resistance. We identiﬁed a novel bacteriocin from Actinomyces ruminicola with no
previously characterized antimicrobial activity. Using publicly available genomic data,
we found a highly conserved yet divergent family of previously unidentiﬁed homol-
ogous peptide sequences within the genus Actinomyces with striking similarity to
eukaryotic defensins. These actifensins may provide a potent line of antimicrobial
defense/offense, and the machinery to produce them could be used for the design
of new antimicrobials given the degeneracy that exists naturally in their structure.
KEYWORDS Actinomyces, bacteriocin, defensin, antimicrobial peptide, actifensin
Novel antimicrobial compounds are increasingly important in the food, agriculture,and medical ﬁelds due to decreasing efﬁcacies of current antimicrobial treatments.
Bacteriocins are ribosomally synthesized antimicrobial peptides produced by bacteria
which can target another bacterium of the same species (narrow spectrum) or bacteria
of other species/genera (broad spectrum) (1). Bacteriocin producers are self-protected
through the production of speciﬁc immunity proteins, and as bacteriocins are gene
encoded, they can be genetically modiﬁed. Bacteriocins produced by Gram-positive
bacteria have been grouped according to their primary structure into class I (posttrans-
lationally modiﬁed bacteriocins) and class II (unmodiﬁed or cyclic bacteriocins) (2). Class
II is split into several subgroups, including the class IId bacteriocins, which are a
heterogenous group of linear, unmodiﬁed, nonpediocin-like peptides (3).
Defensins are antimicrobial peptides ubiquitous among eukaryotes which play a
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role in innate immunity but have also been found to act as signaling peptides, toxins,
enzyme inhibitors, and abiotic stress responders and to have anticancer properties.
Defensins are small (10 kDa) cysteine-rich (forming three to six disulﬁde bonds)
peptides with low amino acid identity, and the two superfamilies are thought to have
evolved convergently (4). Only two expressed defensin-like bacteriocins have been
described; the laterosporulins were previously identiﬁed among prokaryotes and con-
tain disulﬁde bonds in positions homologous to those in eukaryotic defensins (5, 6).
Other disulﬁde bond-containing bacteriocins, such as bactofencin, have been com-
pared with eukaryotic defensins due to their highly cationic nature (7, 8). Laterosporulin
and its homolog laterosporulin10 are class IId bacteriocins produced by Brevibacillus
spp. which have been described as broad-spectrum antimicrobials against both Gram-
negative and Gram-positive bacteria. The two peptides are 5.6 kDa and 6.0 kDa and
share only 57.6% amino acid sequence identity but have conserved cysteines, which are
characteristic of eukaryotic defensins (6).
Actinomyces spp. are a heterogenous group of high-GC-content, Gram-positive
non-spore-forming facultative or obligate anaerobes that belong to the Actinomyceta-
ceae family within the phylum Actinobacteria (9). In humans, a number of species are
known colonizers of hard surfaces in the oral cavity, where they play a key role in
plaque bioﬁlm formation (10, 11). They have been identiﬁed as core members of the
oral bacteriome, present in moderate abundance (0.1% to 2.0%) among geograph-
ically diverse populations (10, 12–15). Actinomyces spp. have been implicated in oral
health as being associated in greater abundance in individuals with dental caries, one
of the most prevalent chronic oral diseases worldwide (14, 15). Most characterized
strains are clinical isolates of human origin, while some opportunistically pathogenic
species such as Actinomyces israelii and Actinomyces gerencseriae are known to cause
the uncommon infectious disease actinomycosis (16). Though Actinomyces spp. are
abundant in the oral cavity, little is known about their presence in the gut, probably
due to their low abundance (0.1%) (10). Many Actinomyces spp. have been isolated
from fecal material and from the gastrointestinal tracts of different animals, indicating
a propensity for gastric transit survival, and their presence has also been noted in the
urogenital tract (17–24). Here, we identify a new group of bacteriocins using a pan-
genomic in silico approach paired with functional screening. Many in silico genome
mining tools have been developed for the successful detection of novel antimicrobial-
producing operons (25, 26). Obviously, these methods rely on relationships with
previously known genes; therefore, functional screening is crucial for the identiﬁcation
of unrelated antimicrobials. In this study, we isolated a potent bacteriocin-producing
strain of Actinomyces ruminicola from sheep feces; the bacteriocin produced resembled
eukaryotic defensins, having three characteristic disulﬁde bridges. A subsequent pan-
genus Actinomyces analysis revealed that such bacteriocins are widely distributed in
these bacteria, albeit with a highly variable structure.
RESULTS
Identiﬁcation of a novel bacteriocin-producing Actinomyces sp. Actinomyces
ruminicola DPC 7226 was isolated from sheep feces. During an initial screen of10,000
colonies for bacteriocin producers, this strain was found to produce a large zone of
inhibition when overlaid with an acid-tolerant indicator species, Lactobacillus del-
brueckii subsp. bulgaricus LMG 6901 (Fig. 1a). The neutralized cell-free supernatant (CFS)
was also found to produce a zone of inhibition against L. delbrueckii subsp. bulgaricus
LMG 6901, indicating production of a soluble antimicrobial molecule (Fig. 1b). This
activity was eliminated when the supernatant was treated with proteinase K, demon-
strating that the antimicrobial is proteinaceous in nature (data not shown).
Antimicrobial activity was puriﬁed from pelleted bacterial cells (C18 SPE; reversed-
phase high-performance liquid chromatography [HPLC]) and CFS (Amberlite XAD, C18
SPE; reversed-phase HPLC), and matrix-assisted laser desorption ionization–time of
ﬂight mass spectrometry (MALDI-TOF MS) of active peaks detected a mass of
4,091 1 Da (Fig. 2a and b). The mass was also detected by colony MS (Fig. 2c). The
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activity of the HPLC-puriﬁed fraction from CFS was assayed against L. delbrueckii subsp.
bulgaricus LMG 6901 and found to be active at1 g · ml1 (Fig. 2d). The antimicrobial
peptide was found to be heat stable, retaining almost all activity after treatment for 30
min at 100°C, but was completely lost after treatment at 121°C for 15 min.
Spectrum of inhibition. A range of indicator organisms was tested against the
puriﬁed antimicrobial to determine the spectrum of inhibition. The antimicrobial was
active against a broad range of genera, with 22 of the 27 strains screened inhibited to
various degrees, including species of the genera Lactococcus, Enterococcus, Lactobacil-
lus, Streptococcus, Pediococcus, Bacillus, Staphylococcus, other Actinomyces spp., and
Clostridium spp. (Fig. 3). No inhibition against the Gram-negative species Salmonella
enterica or Escherichia coli was observed. Listeria spp. and Bacillus spp. were inhibited
weakly or not at all (Fig. 3). Inhibition against other Actinomyces spp. was found, and
activity was particularly strong against Staphylococcus aureus and Clostridium difﬁcile.
MICs were determined against Enterococcus faecium APC1031, E. faecium NCDO0942, S.
aureus R693, Streptococcus agalactiae APC1055, and C. difﬁcile DPC6534 (see Fig. S1 in the
supplemental material). Enterococci were inhibited at 3.05 to 6.1M. S. aureus was inhib-
ited at 3.05M. S. agalactiae and C. difﬁcile were inhibited at 0.76M (Fig. S1).
Distribution of genes encoding bacteriocins in the genus Actinomyces. As the
active mass could not be matched to any previously known antimicrobial peptide and
no antimicrobial compounds were previously described within the species, the genome
of A. ruminicola DPC 7226 was sequenced. Following genome annotation, the draft
genome was analyzed using BAGEL4 to search for potential antimicrobial-encoding
operons. Gene clusters were identiﬁed containing putative genes for thiopeptide
production (data not shown), but the masses predicted, 2,195.4 Da and 1,152.5 Da, did
not correspond with the mass detected in the antimicrobial HPLC fraction.
In conjunction with screening of the genome of A. ruminicola DPC 7226, we also set
out to characterize the antimicrobial potential of the genus. One hundred sixty-one
Actinomyces species genomes in various stages of assembly were screened using
BAGEL4 (see Table S1). The isolates were obtained from humans (78.2%) or other
animals (16.1%) or were of unknown origin (4.9%), while one was an environmental
isolate (0.6%). One hundred six areas of interest were revealed in 76 strains, covering 18
species. Ninety areas of interest contained complete operons for antimicrobial produc-
tion. Twenty-nine were predicted to encode class I bacteriocins, including 7 LanBC
modiﬁed lantibiotics, 16 LanM modiﬁed lantibiotics, 1 single-peptide sactibiotic, 3 lasso
peptides, and 2 thiopeptides. Thirteen operons were predicted to encode class IId
bacteriocins, and a further 48 operons were predicted to encode bacteriolysins. A
phylogenetic tree was generated from the 16S rRNA sequences of 142 Actinomyces
genomes with Bacteroides fragilis ATCC 25285 as the root and overlaid with operon type
and strain source (Fig. 4). Bacteriocin production was widely distributed across the
Actinomyces pangenome, though bacteriolysin production was found exclusively
among human isolates (Fig. 4).
FIG 1 Antimicrobial activity of Actinomyces ruminicola DPC 7226 from colonies overlaid with L. delbrueckii
subsp. bulgaricus LMG 6901 in sloppy MRS (a) and in well diffusion with neutralized CFS (b).
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Genetic and molecular characterization of the actifensin determinant. To iden-
tify the gene encoding the 4,091 (1)-Da peptide within the genome of A. ruminicola
DPC 7226, pure peptide was subjected to N-terminal sequencing, which revealed a
primary sequence consisting of Gly-Phe-Gly-X-Asn-Leu-Ile-Thr-Ser-Asn-Pro-Tyr-Glu-X-
Ser, with blanks at residue positions 4 and 14 denoted as probable cysteines (Fig. 5a).
This 15-amino-acid sequence was matched to a 69-residue small open reading frame in
the draft genome, capable of encoding a 37-amino-acid mature peptide (hereafter
referred to as actifensin) with a predicted mass of 4,097.7 Da preceded by a 32-residue
leader sequence (Fig. 5a).
FIG 2 Detection of actifensin 4,091 Da  1 Da (indicated by arrows) by MALDI-TOF MS from cell-free supernatant (a), cell extract (b), and colonies on a plate
(c). (d) The 4,091 (1)-Da compound when puriﬁed was active to 1 g · ml1; indicator, L. bulgaricus LMG 6901.
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The genetic locus encoding actifensin is shown in Fig. 5b, where afnA encodes
actifensin. Within an approximately 6.5-kbp upstream region of afnA, genes encoding
an ABC transporter permease (afnJ), an ATP binding ABC transporter (afnK), and
another ABC transporter permease (afnL) were identiﬁed as being present. Downstream
of afnA, three hypothetical genes of unknown function (afnG to afnI) were found,
followed by genes encoding another ATP binding ABC transporter (afnF), a predicted
/ hydrolase superfamily protein (afnE), another protein of unknown function, a
subtilisin-like protease, and a LuxR family transcription factor (afnD, afnC, and afnB,
respectively). Within afnE is a predicted RHO-independent transcription terminator, and
upstream of the structural gene are four predicted promoters. A putative ribosome
binding site was also identiﬁed nine base pairs upstream of the ATG start codon for the
peptide consisting of a purine rich sequence, 5=-GAAAGG-3= (Fig. 5a).
The leaderless structural peptide was found to have a predicted mass of
4,097.7 Da. This mass was approximately 6 Da higher than detected by MALDI-TOF
MS. The difference between predicted and observed masses most likely corre-
sponds to the loss of six hydrogen atoms during the formation of disulﬁde bonds
between the six cysteines. Short peptides with numerous disulﬁdes in speciﬁc
positions are characteristic of the defensin peptide families (4). To conﬁrm the
presence of disulﬁde bonds in actifensin, pure peptide was reduced and alkylated to
break open the disulﬁde bonds and then subjected to trypsin digestion and peptide
mass ﬁngerprint analysis by MALDI-TOF MS. Reduction and alkylation of actifensin
resulted in a 4,440-Da mass, which correlates with the expected increase in mass of
58 Da for each cysteine. MALDI-TOF MS analysis of the subsequent trypsin digest
detected a mass of 2,257.02 Da, which corresponds to the ﬁrst 19 amino acids of the
peptide (Gly-1 to Lys-19) containing three alkylated cysteine residues. Three other
predicted masses for Ser-20 to Arg-24, Gly-25 to Arg-31, and Thr-32 to Tyr-37 (predicted
and alkylated masses of 581.30 Da, 584.25 Da, and 803.31 Da, respectively) were not
detected.
Discovery of actifensin homologs. BLASTp analysis with AfnA found homologous
open reading frames (ORFs) within the fungal genera Blastomyces, Emmonsia, and
Emergomyces, Helicocarpus griseus, and a defensin from the mollusk species Ruditapes
philippinarum (58%, 58%, 55%, 52%, and 61% identity, respectively) (see Fig. S2).
Characteristic conserved cysteines were noted, though low sequence identity was
observed between the mature actifensin peptide and eukaryotic defensins. The same
FIG 3 Inhibition of actifensin against a broad spectrum of indicator species. Weak inhibition, 0.5- to 3-mm zone; strong inhibition, 3- to 5-mm zone; very strong
inhibition, 5-mm zone. VRE, vancomycin-resistant Enterococcus; MRSA, methicillin-resistant Staphylococcus aureus.
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FIG 4 Phylogram of Actinomyces genomes using 16S sequences overlaid with BAGEL4 predictions, strain source, and presence of actifensin or predicted
homolog operon.
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was found when AfnA was compared with known previously characterized arthropod,
ascomycete, and mollusk defensins (Fig. 6a) with conserved secondary structures (Fig.
6b). BLASTp analysis using the 69-residue AfnA sequence identiﬁed 37 homologous
structural genes within the genus Actinomyces and one homolog from a Corynebacte-
rium sp. sequence (Fig. 7a). Further analysis indicated that the homologs were present
in 15 operons from 14 strains, in addition to conserved genes for transport, transcrip-
tion regulation, and proteolytic activity (Fig. 7b). Actinomyces sp. strain 2119, Actino-
myces oris S64C, Actinomyces succiniciruminis AM4, A. oris CCUG34286, Actinomyces sp.
strain F0337, Actinomyces sp. strain HMSC075C01, and A. oris MMRCO6-1 had at least
two actifensin homologs, while Actinomyces sp. F0337 contained an operon with seven
copies, the most observed within one genome (Fig. 7b). The genome of A. oris
MMRCO6-1 contained six encoded actifensin homologs detectable over two contigs,
but only one (contig 50) contained the other conserved ORFs (afnB-I and afnJ-K) present
in the actifensin operon. Twelve of 14 operons had a highly conserved arrangement of
afnB-I, all of which also had ABC transporter genes directly upstream of the bacteriocin
ORF. The mean amino acid identity between all structural genes was 52%. The highest
identity observed between actifensin and a homolog was 77% identity with afnA in
Actinomyces sp. strain CTC72, though higher identities were observed between other
peptides (see Fig. S3). We proceeded to characterize ten predicted cysteine-stabilized
 (CS) peptides predicted by Dash et al. (27). The peptides are present in ﬁve
Actinomyces genomes bringing the total number of peptides to 47 homologous
structural genes in 19 strains. Actinomyces oris S24V, Actinomyces denticolens PA,
Actinomyces sp. strain Chiba-101, Actinomyces johnsonii F0542, and Actinomyces sp.
strain F0330 have genes which were not identiﬁed using BLASTp and the actifensin
propeptide sequence (27). Strains S24V, PA, and Chiba-101 display the conserved afnB
to afnI ORFs following afnA, which are absent in strains F0330 and F0542 (Fig. 7b).
The propeptide contains a conserved G-X-E motif prior to the start of the mature
peptide (Fig. 7a). In 36 of the peptides, an alanine residue is present after the glycine,
which may be involved in secretion and cleavage. This putative GA cleavage signal is
replaced by a TS motif in 8 of the 49 peptides (A. oris S64C afnA5, A. oris CCUG34286
afnA7, A. oris MMRCO6-1 contig 75 afnA2, Actinomyces sp. F0337 afnA4, Actinomyces sp.
FIG 5 (a) Sixty-nine-residue propeptide identiﬁed following genome analysis using the 15-amino-acid sequence (underlined) determined by N-terminal amino
acid sequencing. RBS, putative ribosome binding site highlighted 8 bp upstream of the start codon. (b) Genetic vicinity of structural gene containing nearby
genes for transport, hypothetical and proteolytic proteins, and a transcription factor.
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HMSC075C01 afnA4, A. oris MMRCO6-1 contig 50 afnA4 and afnA3, and A. oris S24V
afnA5). A conserved Pro residue was noted following the ﬁrst conserved Cys in addition
to a conserved G-Y-X-G-G-X-C sequence at positions 56 to 62 of the propeptide (22 to
28 in the active peptide) (Fig. 7a).
DISCUSSION
We describe a novel group of bacteriocins with broad-spectrum inhibitory activity
within the Actinomyces genus. Actifensin is the ﬁrst such bacteriocin to be discovered,
which is produced by a strain of Actinomyces ruminicola.
Actifensin inhibited a broad range of Gram-positive species, including notable
pathogens such as vancomycin-resistant Enterococcus and methicillin-resistant Staph-
ylococcus. Given the global challenge of the increase in antibiotic resistance, there is an
urgent need for new classes of antimicrobials. Bacteriocins have been suggested as an
alternative to conventional antibiotics due to their effectiveness at low concentrations
and their potential to be genetically modiﬁed (2). Class II bacteriocins are diverse in
sequence and structure whose mechanism of action is through interaction with the cell
membrane, causing permeabilization and pore formation and dissipating the mem-
brane potential (3). The defensin-like bacteriocin laterosporulin10 has been found to
act on the cell membrane of S. aureus Mtb H37Rv, disrupting cellular homeostasis (6).
Plectasin and eurocin, fungal C6 defensins, are known to bind lipid II, inhibiting
bacterial cell wall biosynthesis (45, 46). Actifensin possesses an N-terminal loop exten-
sion which, in other defensin peptides, has been implicated in membrane disruptive
capability (31). The loop consists of nine residues between Cys-4 and Cys-14 beginning
with an Asn. In most of the other peptide sequences identiﬁed, the N loop is six
residues long, beginning with a Pro (except in AfnA from Actinomyces sp. strain F0588
or A. naeslundii S44D, which has an eight-residue N loop with a serine or arginine in the
ﬁrst position, respectively, followed by a Pro) (Fig. 7a).
Actifensin also inhibited the growth of C. difﬁcile and Clostridium sporogenes. Clos-
tridia are known colonizers of the rumen, and as A. ruminicola DPC7226 was isolated
FIG 6 (a) Mature peptide sequence alignment of AfnA with characterized defensin family peptides from different phyla. Known disulﬁde connectivities are
outlined above highlighted cysteine residues. (b) Available 3D structures of sequences in panel a. Alpha helices are colored red, and beta sheets are shown in
blue. Protein data bank accession numbers shown below the structres (in parentheses).
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FIG 7 (a) Sequence alignment of actifensin propeptide sequence (boxed) with structural genes predicted for Actinomyces sp. peptides.
Amino acids with greater than 80% conservation are colored, and leader sequences and mature active peptides are indicated at the top.
Putative disulﬁde connectivity between conserved cysteines of the mature peptide is indicated at the bottom right, and putative cleavage
sites are indicated at the bottom center. (b) Diagrams of actifensin homolog production operons. Multiple bacteriocin genes within one
operon are denoted afnA1 to afnA7 where present.
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from the feces of a ruminant, actifensin production may provide a competitive advan-
tage in the gut microbiome. Actinomyces neuii and Actinomyces radingae were both
inhibited by actifensin; however, it would be interesting to see if cross-resistance
between actifensin and other actifensin-like producers exists.
A pangenus in silico screen revealed that the genus Actinomyces (Fig. 4) is a rich
source of antimicrobials and has genes for bacteriolysin and lantibiotic production
(48/90 and 29/90 operons, respectively). Thirteen class II bacteriocins were predicted by
BAGEL, but neither the actifensin operon nor its homologs were detected due to lack
of similarity with known systems. One previous study described odontolycin, a bacte-
riocin produced by an Actinomyces odontolyticus dental plaque isolate, though no
further research on the peptide was reported (34). Interestingly, in our study, no
operons for bacteriocin production were found among ﬁve A. odontolyticus genomes
screened (Fig. 4).
The actifensin structural gene encodes a 37-amino-acid mature peptide preceded by
a 32-amino-acid leader sequence (Fig. 5). A GA motif at positions 3 and 2 was
identiﬁed, which is a known cleavage signal used in ABC transporter-mediated secre-
tion (36). Indeed, there are a number of predicted ABC transporter genes within the
actifensin operon. ABC transporter genes could also play a role in self-immunity to the
actifensin peptide. Unusually, an additional glutamic acid residue is present at position
1 before the mature peptide. As the puriﬁed peptide was subjected to N-terminal
sequencing, we can be certain that the mature peptide begins with a glycine residue.
Therefore, the additional glutamic acid residue at position 1 is most likely subject to
exopeptidase cleavage prior to activity, and indeed, there are genes present with
predicted protease activities (Fig. 5).
The GA cleavage motif is present in 36 of the homolog structural genes, with TS
replacing the motif in eight instances, GT and GG in two cases, and GS, SA, and DA in
one each (Fig. 7a). A double glycine is the most commonly found motif for ABC
transporter-mediated cleavage among bacteriocins, though GA and GS have also been
observed (36). It will be interesting to see if the peptides bearing other residues at this
location are indeed subject to ABC-mediated transport. We note that each operon
containing a gene with a nontraditional TS/GT/SA/DA signal contains at least one more
structural gene than those with a GG/GA sequence. This could indicate potential
diversiﬁcation of a repertoire of bacteriocins enabling improved ability to combat
multiple competitors. It was also surprising that an actifensin homolog was found in a
distantly related Corynebacterium sp., though many of the conserved genes in the
Actinomyces sp. operons were not present (Fig. 7b). As such, this may be nonfunctional,
as ABC transporter-related genes are missing upstream of the structural gene and the
conserved afnB to afnI pattern is absent. The genera Corynebacterium and Actinomyces
are distantly related members within the phylum Actinobacteria, and some species are
known members of plaque bioﬁlms, providing an opportunity for horizontal gene
transfer (16). However given the dissimilarity of the operons, they may have been
acquired independently at some stage.
As stated above, the laterosporulins produced by Brevibacillus spp. are two struc-
turally defensin-like bacteriocins with broad-spectrum inhibitory activity (5, 6). Their
amino acid sequences are 57.6% similar, which is comparable to that for actifensin and
its predicted homologs, but share the conserved cysteine residues which form disulﬁde
bridges. Conserved disulﬁdes are characteristic of defensins and are present in verte-
brate, invertebrate, plant, fungal defensins, and defensin-like peptides (4). Actifensin
has a predicted mass of 4,097.7 Da, but the actual mass is 4,091 1 Da by MALDI-TOF
MS. The same discrepancy in predicted and observed masses was noted with laterospo-
rulin, where six hydrogen atoms are lost in the formation of disulﬁde bonds. We
hypothesize that bonds in actifensin likely form in the 1-4, 2-5, and 3-6 formations,
similar to that in ascomycete and arthropod C6 defensins (Fig. 6), as the amino acid
motifs (C-X5–12-C-X3-C-X9–10-C-X4–5-C-X-C) are conserved (5). The structure of lat-
erosporulin10 has been determined to be architecturally similar to human -defensin,
though its disulﬁde connectivity is homologous to that of -defensins (Fig. 8) (6). The
Sugrue et al. Journal of Bacteriology
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overall architecture and disulﬁde connectivity of actifensin are likely to be homologous
to those of C6 defensins, consisting of an N-terminal -helix followed by a two-stranded
antiparallel -sheet stabilized by disulﬁde bridges (Fig. 8). Interestingly, an actifensin
homolog we identify as AfnA from Actinomyces sp. oral taxon 171 strain F0337 has had
its three-dimensional (3D) structure determined and is publicly available under PDB
accession number 2RU0. The peptide labeled actinomycesin is strikingly similar to C6
fungal and arthropod defensins, which have also been characterized (Fig. 6); however,
no published material is available regarding its activity, antimicrobial or otherwise.
Indeed, two antiparallel beta sheets stabilized by disulﬁde bonds with an interposed
short turn region, previously described as the -core motif, are a ubiquitous feature of
antimicrobial peptides (35). Actifensin exhibits the highly conserved GXC (positions 26
to 28 in the mature peptide) as do all of its homologs.
CS peptides comprise one of the most widespread families of defensins and
defensin-like peptides. A recent publication identiﬁed a number of CS sequences in
bacterial genomes with potential for antimicrobial, toxin, or signaling activity (27). Of 58
peptides identiﬁed within the phylum Actinobacteria by Dash et al. (27), 34 were of the
genus Actinomyces, 24 of which we identiﬁed using BLAST with the actifensin propep-
tide sequence (see Table S2 in the supplemental material). A further 113 bacterial
peptide sequences identiﬁed by Dash et al. (27) remain to be characterized from a
functional perspective and may be a potent source for antimicrobials. Interestingly, a
bacterial defensin-like peptide, AdDLP, identiﬁed in silico was synthesized and recom-
binantly expressed, and the peptide was found to have anti-Plasmodium activity (28).
The bacterial CS peptides may be an untapped source of potential applications and
have been proposed as the ancestral evolutionary origin of eukaryotic defensins (29).
In the search for novel antimicrobials for application in health and food, genomic
and pangenomic approaches are becoming increasingly common (25, 26). These
approaches are advantageous in that large amounts of genetic data can be analyzed to
FIG 8 Conserved structures of the defensin peptide superfamily and defensin-like bacteriocins, laterosporulin and
actifensin.  sheets are colored blue,  helices are colored red, and disulﬁde bonds are shown in yellow.
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identify novel antimicrobials/bacteriocins and can even allow one to “reincarnate”
otherwise “dormant” genes (47). However, such analyses are dependent on the ability
of programs to predict based on databases of previously identiﬁed sequences, and so
peptides with novel structures and operons may not be detected. Though a number of
bacteriocin operons were found in the Actinomyces spp. genomes using BAGEL, ac-
tifensin was not identiﬁed by genome sequence alone, which highlights the impor-
tance of functional screening for antimicrobial compounds in addition to in silico
screening. By using BLAST, 37 structural genes with homology to actifensin were found
in Actinomyces spp. along with a single structural gene from a Corynebacterium sp. As
some CS peptides function as toxins, future applications will require any potential
cytotoxic effects to be assayed. We propose that actifensins and the laterosporulins
may constitute a new subgroup of class II bacteriocins: the defensin-like bacteriocins.
These bacteriocins share only moderate identity to each other but contain highly
conserved cysteine residues and are structurally related to eukaryotic defensins.
Conclusions. A series of novel defensin-like bacteriocins within the genus Actinomyces
were identiﬁed using an in silico pangenomic approach coupled with a functional screen.
The bacteriocins represent a potential new class of antimicrobial peptides, defensin-like
bacteriocins, whichmay have widespread applications as antimicrobials in food and human
health.
MATERIALS AND METHODS
Isolation of bacteria and identiﬁcation of bacteriocin production. Samples of raw milk, unpas-
teurized cheeses, sheep feces, and honey were serially diluted in maximum recovery diluent (Oxoid) and
plated on several medium types for the isolation of bacteriocin-producing bacteria: Streptococcus
thermophilus selective agar (tryptone, 10.0 g · liter1; sucrose, 10.0 g · liter1; yeast extract, 5.0 g · liter1;
K2HPO4, 2.0 g · liter1; bromocresol purple, 0.03 g · liter1; agar, 15.0 g · liter1) incubated aerobically at
42°C; M17 (Merck) supplemented with 10% (wt/vol) lactose incubated at 30°C aerobically; de Man,
Rogosa, and Sharpe (MRS; Difco) agar supplemented with 30 g · ml1 L-vancomycin hydrochloride
incubated at 37°C; MRS adjusted to pH 5.4 incubated at 42°C anaerobically; Lactobacillus selective agar
(LBS) incubated at 30°C anaerobically; and TOS (transgalactosylated oligosaccharide) agar supplemented
with 50 g · ml1 lithium mupirocin incubated at 37°C anaerobically.
Isolates were subject to an initial bacteriocin production screen by overlaying with 10 ml “sloppy”
MRS agar (7.5 g · liter1 agar) tempered to 50°C and seeded with an overnight culture of Lactobacillus
delbrueckii subsp. bulgaricus LMG 6901 (0.25% [vol/vol]). Cultures which were found to produce distinct
zones of inhibition in the agar overlay were cultured in broth for well diffusion assays. For well diffusion
assays, 20 ml of sloppy MRS agar seeded with L. bulgaricus LMG 6901 as described above was poured and
allowed to set, in which 6-mm-wide wells were then bored. Fifty microliters of cell-free supernatant was
added to each well, and plates were incubated at 37°C overnight. Zones of inhibition were indicative of
antimicrobial activity.
Bacterial strains, media, reagents. Strains used in this study and their incubation conditions are
listed in Table S3 in the supplemental material. A. ruminicola DPC 7226 was routinely maintained in brain
heart infusion (BHI) broth (Oxoid) anaerobically at 37°C. Medium reagents were sourced from Sigma-
Aldrich (Wicklow, Ireland) unless stated otherwise.
Puriﬁcation of actifensin. A. ruminicola DPC 7226 was grown anaerobically and statically at 37°C in
500-ml volumes of BHI broth for 48 h. Following centrifugation, cell-free supernatant was applied to an
Econo column containing 30 g Amberlite XAD beads prewashed with Milli-Q water. The column was
washed with 300 ml 30% ethanol and 300 ml 2-propanol–0.1% triﬂuoroacetic acid (TFA) (IPA). IPA was
removed by rotary evaporation, and the sample was applied to a 60-ml 10-g Strata-E C18 SPE column
(Phenomenex, Cheshire, UK) preequilibrated with methanol and water. The column was washed with
60 ml 25% ethanol and then 60 ml IPA.
Centrifuged cells were combined with 100 ml IPA and stirred at room temperature for 3 to 4 h. The
resulting suspension was centrifuged, and the cell extract and puriﬁed CFS were assayed by MALDI-TOF
mass spectrometry to determine the molecular mass of antimicrobial compounds (Axima TOF2 MALDI-
TOF mass spectrometer; Shimadzu Biotech, Manchester, UK). A MALDI target plate was precoated with
-cyano-4-hydroxycinnamic acid (CHCA) matrix solution, 0.5 l of the supernatant from the cell extract
was then placed on the target, and a ﬁnal layer of matrix solution was added. Positive-ion linear or
reﬂectron mode was used to detect peptide masses.
Actifensin characterization. Characterization was performed using puriﬁed bacteriocin. To test
protease susceptibility, 100-l aliquots of 50 g · ml1 were subjected to treatment with 20 mg · ml1
proteinase K (Sigma-Aldrich) and -chymotrypsin (Sigma-Aldrich) at 37°C for 3 h, followed by a 10-min
incubation at 100°C to denature the enzymes. Fifty-microliter aliquots were assayed on L. delbrueckii
subsp. bulgaricus LMG 6901 indicator plates. Heat stability was determined by 30-min incubations at
60°C, 70°C, 80°C, 90°C, and 100°C and by autoclaving at 121°C for 15 min.
For spectrum of activity, a well diffusion assay was carried out as described above with the
strains in in the appropriate medium. Fifty microliters of puriﬁed bacteriocin at a concentration of
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50 g · ml1 was added to a well. Following overnight incubation under the appropriate conditions,
zones of activity were measured and categorized as no inhibition, weak inhibition (0.5 mm to 2 mm),
strong inhibition (2.5 mm to 5 mm), and very strong inhibition (5 mm). MIC against selected
pathogens was assayed as described above, starting at 100 g · ml1 peptide solution and serially
diluted 1:2 to 0.78 g · ml1.
Draft genome sequencing. DNA was extracted using a GenElute bacterial genomic DNA kit (Sigma)
and prepared for sequencing using a Nextera XT kit (Illumina) for library preparation. DNA was quantiﬁed
using a Qubit 2.0 ﬂuorometer. Sequencing was carried out using an Illumina MiSeq platform with
paired-end 2 300-bp reads by the Teagasc Sequencing Centre, Teagasc Food Research Centre,
Moorepark, Fermoy, Ireland. Assembly was performed using tools available on the public server at
https://usegalaxy.org (30). Assembly was performed de novo using SPADES (version 3.0.0) and resulted
in 116 contigs. Contigs were aligned to a reference genome using Mauve (version 20150226, build 10),
followed by annotation with RAST (version 2.0). The annotated genome was analyzed for predicted
bacteriocin and secondary metabolite production clusters using BAGEL4 (37), and any further annotation
was carried out using Artemis genome browser (version 16.0.0).
BAGEL screen and phylogenetic analysis of Actinomyces species. GenBank and FASTA assemblies
of the genus Actinomyces were acquired from the NCBI assembly database and screened using BAGEL4
(37). Where available, corresponding 16S rRNA sequences were acquired from the RDP database (38), and
where unavailable, Actinomyces sp. genomes were subject to analysis using RNAmmer (32). 16S rRNA
sequences were aligned using MUSCLE (33), and a phylogram was generated using iTOL (40). The
phylogram was then overlaid with the BAGEL screen data.
Reverse bacteriocin identiﬁcation, peptide and structure prediction, and homology. Two
hundred micrograms freeze-dried puriﬁed peptide was sent for N-terminal amino acid sequencing
(AltaBioscience, UK). The resulting 15-residue sequence, GFGXNLITSNPYQXS, was used to search for a
bacteriocin structural gene with Artemis genome browser. Following identiﬁcation of the structural gene,
other genomes were searched for genes homologous to the active and propeptide using BLASTp; genes
on contigs consisting of less than 5 kbp were excluded. Additional actifensin homologs were identiﬁed
from the study by Dash et al. (27) among 147 nonredundant bacterial CS peptide sequences (27).
Alignments were generated using Clustal Omega (41) and visualized with Jalview (42). Structural
modeling was performed using SWISSMODEL (43) online software, and structural images were generated
using PyMOL (44).
Data availability. Genomic data analyzed in this study were deposited in GenBank/EMBL under
accession number SPKK00000000 and are publicly available from the NCBI database at https://www.ncbi
.nlm.nih.gov/.
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